US 10,300,129 B2 · Epstein-Barr-virus vaccine

Abstract

The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according in the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.

Claims9

Dependent claims

A method for eliciting CD8+ T-cells specific for an EBV antigen in a subject, comprising administering to said subject an Epstein-Barr virus-like particle (VLP), thereby eliciting CD8+ T-cells specific for an EBV antigen;

wherein the VLP comprises at least one difference in comparison to a wildtype EBV genome lacking one or more sequences encoding EBV polypeptides that are required for B-cell transformation and/or comprising one or more sequences encoding EBV polypeptides whose B-cell transformation capacity is disabled,
wherein the polypeptide whose transformation capacity is disabled is the LMP-1 polypeptide.

A method of generating an Epstein-Barr virus-like particle (VLP), the method comprising:

(a) transfecting a cell with a modified EBV genome, wherein said modified EBV genome in comparison to a wildtype EBV genome at least lacks one or more sequences that are required for the packaging of said wildtype EBV genome, and/or comprises one or more sequences encoding EBV polypeptides whose packaging capacity is disabled;
(b) culturing the cell obtained in step (a) under conditions that allow expression of said modified EBV genome;
(c) inducing the replicative phase of EBV;
and
(d) isolating said particle,
wherein said modified EBV genome further comprises at least one difference in comparison to a wildtype EBV genome lacking one or more sequences encoding EBV polypeptides that are required for B-cell transformation and/or comprising one or more sequences encoding EBV polypeptides whose B-cell transformation capacity is disabled and wherein the polypeptide whose transformation capacity is disabled is the LMP-1 polypeptide.

3 more elements

Dependencies are inferred from the claim text.

Epstein-Barr-virus vaccine

Life of this patent

Epstein-Barr-virus vaccine

Life of this patent

Abstract

Claims9